SEATTLE--(BUSINESS WIRE)--Research findings presented at the 2008 American College of Allergy, Asthma and Immunology (ACAAI) Scientific Meeting revealed a significant cost savings associated with allergy immunotherapy (IT) in children with allergic rhinitis (AR). This pioneering study, supported by Greer, was summarized during an oral presentation by Cheryl Hankin, Ph.D., President and Chief Scientific Officer of BioMedEcon and principal investigator of the study, at the ACAAI meeting, held Nov. 6-11 in Seattle, Wash.
